Abstract:
In rheumatological practice, nonsteroidal anti-inflammatory drugs (NSAIDs) remain of
great importance in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis
(AS), osteoarthrosis (OA), gout, etc., the widespread use of which is due to the relief of
pain and inflammation, which are the main clinical manifestations of rheumatological
diseases (RH). At the same time, it is reliably known that regular use of NSAIDs is
associated with a number of side effects and risks, the leader of which is inflammatory,
erosive, and ulcerative changes in the mucous membrane of the gastrointestinal tract
(GIT) [13, 14]. One of the unresolved issues is the occurrence of secondary damage from
the gastrointestinal tract (GI).
